Skip to main content
Erschienen in: Reactions Weekly 1/2017

01.03.2017 | News item

TGA: do not use Zostavax in immunocompromised patients

Erschienen in: Reactions Weekly | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

Patients with compromised immune function should not use the Zostavax vaccine as there is a risk of complications (including death) from infection, says Australia's TGA.1
Fußnoten
1
TGA = Therapeutic Goods Administration
 
2
nerve pain due to damage caused by varicella-zoster virus
 
Metadaten
Titel
TGA: do not use Zostavax in immunocompromised patients
Publikationsdatum
01.03.2017
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2017
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-017-27777-0

Weitere Artikel der Ausgabe 1/2017

Reactions Weekly 1/2017 Zur Ausgabe

Case report

Bupivacaine

Case report

Donepezil

Case report

Gefitinib

Case report

Bupropion

Case report

Minocycline

Case report

Triamcinolone